TEL AVIV, Israel, Jan. 31, 2012 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, today announced the appointment of Dr. James Barry to its Board of Directors as an independent director. Dr. Barry is an experienced medical technology executive and former senior executive at Boston Scientific with a proven track record of bringing products to market, including the TAXUS® paclitaxel-eluting coronary stent.
Ofir Paz, InspireMD's Chief Executive Officer and co-founder, commented, "We are pleased to have Dr. Barry join the Board of Directors. His extensive medical technology experience and reputation, in particular with interventional cardiology products, will be great assets to InspireMD. As we move forward with the further development of our MGuard™ stent technology and position the company for worldwide commercial launch, we continue to seek out seasoned industry experts who can provide support and guidance."
"I am thrilled about joining InspireMD's Board at this exciting stage in the Company's development," said Dr. Barry. "I believe that InspireMD is poised to become an important global player in interventional cardiology and look forward to assisting in the Company's advancement."
Dr. Barry has over 20 years of experience in leadership roles in the medical device industry. He is currently Executive Vice President and Chief Operating Officer at Arsenal Medical Inc. Prior to joining Arsenal, Dr. Barry was Senior Vice President, Corporate Technology Development at Boston Scientific where he was in charge of the Corporate R&D and Pre-clinical Sciences functions. Dr. Barry joined Boston Scientific in 1992 and oversaw its efforts in the identification and development of drug,
|SOURCE InspireMD, Inc.|
Copyright©2010 PR Newswire.
All rights reserved